GlassScriptPhysician profile
Tonya L Hill
NPI 1851427983
$3,741.11
in general payments reported to CMS, 2019-2025
35 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $842 · 2021: $398 · 2022: $414 · 2023: $450 · 2024: $665 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $401.62 | 2019-2023 | |
| Amgen INC. | $345.31 | 2019-2024 | Evenity, Prolia |
| Corcept Therapeutics | $317.83 | 2023-2025 | Korlym |
| Novo Nordisk INC | $287.38 | 2019-2023 | Wegovy |
| Abbvie INC. | $200.33 | 2020-2024 | |
| Glaxosmithkline, LLC. | $180.44 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $170.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $165.06 | 2020-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $162.86 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $155.34 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $149.91 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $142.51 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.43 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.92 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.65 | 2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $81.98 | 2019-2021 | |
| Dexcom, INC. | $79.39 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $70.40 | 2019-2022 | |
| Mylan Specialty L.P. | $66.02 | 2020-2024 | Yupelri |
| Abbott Laboratories | $65.33 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $50.34 | 2024-2025 | Auvelity |
| Viatris Specialty LLC | $49.12 | 2025 | Yupelri |
| Amarin Pharma, INC. | $47.02 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $34.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.20 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.44 | 2023 | Austedo Xr |
| Daiichi Sankyo INC. | $14.27 | 2020 | |
| Currax Pharmaceuticals LLC | $13.60 | 2024 | Contrave |
| Circassia INC. | $13.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.00 | 2023 | Rexulti |
| Medtronic Vascular, INC. | $12.15 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.55 | 2021 | |
| Allergan, INC. | $11.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.